Looking to invest, acquire, license, or partner?
From leveraging linker technology of ADCs to improve the uptake of radioligands, demonstrating the advantage of dual, immunostimulatory or small molecule degraders as more potent payloads, or increasing tissue penetration propensity through novel conjugates to achieve better intracellular exposure; pharma is continuing to prioritize earlier external ADC assets to augment their internal programs.
Why do ADC Companies Want to Collaborate with Pharma?
- Improving understanding of pharma’s targets of interest, to refine fit and differentiation within the market
- Validating and increasing pharma’s awareness around technology platform’s ability to work in the way intended, and advance more selectivity, less resistance, and better potency of ADCs
- Gaining access to non-dilute capital to increase the cash flow runway, and advancing clinical validation through shared resources and risk
What do Pharma Gain from In-Licensing or Research Collaborations with Biotech Advancing Disruptive ADC Science?
- Expanding targetable landscape and opportunity to be first-in-class by pursuing underexploited targets
- Optimizing payload release to reduce off-target effects or overcome challenges of resistance
- Increase tissue penetration propensity to achieve more significant internalization and intracellular exposure to payloads with novel conjugates
Testimonials
From Pharma:
Global Search & Evaluation Lead, Pharma Partnering, Roche: “The focused niche really increased the impact for us overall. Thanks for including us in the program.”
Associate Director, Business Development Seach & Evaluation, BMS: “It was stellar; I heard this sentiment echoed throughout. We appreciated the focused discussions, and intimate setting allowed for easier networking”
Executive Director, Business Development, Merck: “I thought it was fantastic – operationally excellent and thoughtfully designed.”
Senior Director of Acquisitions & Licensing, J&J: “It was a great group of high-quality companies/people in the perfect setting.”
Senior Director, Business Development, Sanofi: “I liked the format: the panel and icebreaker session was a great start and helped with the 1:1s with the companies. The companies knew what Sanofi was looking for and made the 30-minute meetings very efficient”
From Biotech:
Chief Scientific Officer: “We could see how other companies were pitching and we had very clear messaging from pharma companies as to what they were looking for in terms of how you pitched. We came back and made a lot of changes to our decks for BIO Europe in the Autumn, and we got a lot of traction then there, likely because of the changes we made to our decks from the insights we got at this conference.”
Chief Executive Officer: “From my perspective this has been as efficient, or more efficient than BIO, in terms of meeting pharma and getting exposure to the ecosystem. The best part was this focused conference only involves people who are interested in the same things we are interested in. All the conversations I had were very focused. This has been an excellent process”
Chief Business Officer: “The attendee list stood out as our reason to not only enjoy the conference but to prioritize the meeting as a strategic opportunity to meet pharma and biotech counterparts all attending for partnering discussions. One-of-a-kind meeting!”